All sales were pre-planned under 10b5-1 plans, so the cluster does not signal a change in insider sentiment. Monitor the upcoming supplemental NDA filing for aficamten and any subsequent insider activity for directional cues.
Drug in focus
CYTK drug pipeline →MYQORZO
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Next catalyst
- None dated
What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $56.13entry
- T+1 · 16h ago −5.27%α −3.36% · $53.17
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Cytokinetics insiders, including the CEO and EVP of R&D, sold a total of $824K in open-market sales over a week, all under 10b5-1 plans. The sales follow a strong Q3 2026 earnings beat and reaffirmed guidance, but the CEO's $471K sale is material relative to the $8.2B market cap (0.006%). The cluster is neutral given the small size relative to market cap and the pre-planned nature of the trades.
Key Financial Metrics
Key Facts
- CEO Blum sold 7,500 shares for $471K on 2026-11-02 under a 10b5-1 plan
- EVP Malik sold 3,500 shares for $220K on 2026-11-03 under a 10b5-1 plan
- Director Parshall sold 5,000 shares total ($273K) on 2026-11-09 under a 10b5-1 plan
- Total open-market sales: $824K, or 0.01% of $8.2B market cap
- All sales were pre-planned under 10b5-1 trading plans
- Q3 2026 earnings beat consensus on revenue ($47.6M vs $42.3M) and EPS (-$1.37 vs -$1.41 consensus)
- Company reaffirmed 2026 guidance and plans to file supplemental NDA for aficamten in Q4 2026
Financial Impact
Total insider sales of $824K represent 0.01% of market cap, well below the 0.1% materiality threshold
Risk Factors
- Insider sales are small relative to market cap and pre-planned, limiting their informational value
- No unplanned insider buying to offset the sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1794519742056 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Viewing Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers